United States Spinal Cord Stimulation Market is expected to reach US$ 4.66 billion by 2032 | Top 3 key players - Medtronic plc, Abbott Laboratories, Synapse Biomedical (SBI).

Market Size and Growth:

The Global Spinal Cord Stimulation Market size reached US$ 2.96 billion in 2024 and is expected to reach US$ 4.66 billion by 2032, growing with a CAGR of 7.9% during the forecast period 2025-2032. The Market is growing due to the rising prevalence of chronic pain, advancements in neuromodulation technologies, and increasing adoption of minimally invasive spinal cord stimulation therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/spinal-cord-stimulation-market?sz

The Spinal Cord Stimulation (SCS) Market involves the development, manufacturing, and commercialization of implantable devices that deliver electrical impulses to the spinal cord. These devices manage chronic pain, especially in patients unresponsive to conventional therapies. The market encompasses neuro stimulation systems, accessories, and software, driven by rising chronic pain prevalence, technological advancements, and increasing adoption of minimally invasive pain management solutions.

Industry Recent Developments:

United States:

✅ June 2025: The market is projected to reach over USD 3 billion, driven by advancements in rechargeable technology and increased adoption for chronic pain management, with regulatory support emphasizing minimally invasive procedures.​

✅ September 2025: Innovations include the integration of wireless, remote monitoring systems and AI-enhanced device programming, which are improving patient outcomes and device management, reinforcing the US's leadership in neuromodulation technology.​

✅ October 2025: Legal actions and lawsuits related to defective spinal cord stimulators continue to emerge, highlighting ongoing concerns about device safety and the importance of regulatory scrutiny within the industry.​

Japan:

✅ August 2025: Japan's SCS systems market is forecasted to grow at a CAGR of 6.9% through 2030, fueled by the country's aging population and technological advancements in neuromodulation.​

✅ September 2025: The market is characterized by the integration of AI and IoT technologies, with a focus on improving therapy precision and expanding applications beyond pain management, including neurological disorders.​

✅ October 2025: The country's market growth is further supported by government policies promoting healthcare innovation and the development of next-generation, less invasive neural devices.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/spinal-cord-stimulation-market?sz

Major 5 Key Players:

1. Medtronic plc:
Overview: Medtronic is a global leader in medical technology, offering a range of spinal cord stimulation systems designed to manage chronic pain.

Key Products:

InceptivTM: A closed-loop, rechargeable neurostimulator that automatically adjusts therapy in real-time to treat chronic pain.

VantaTM: A high-performance, recharge-free neurostimulator approved by the FDA for long-term pain relief.

IntellisTM: A compact, MRI-safe device offering personalized pain relief through advanced programming.

Strategic Focus: Medtronic emphasizes long-term pain relief, improved quality of life, and cost savings compared to conventional medical management and reoperation.

2. Abbott Laboratories:
Overview: Abbott provides comprehensive neuromodulation therapies, including spinal cord stimulation systems, to manage chronic pain and movement disorders.

Key Products:

EternaTM: The world's smallest rechargeable spinal cord stimulator, offering optimized recharging and long-lasting therapy.

ProclaimTM: A system delivering targeted stimulation to the spinal cord, dorsal root ganglion, or brain, depending on patient needs.

Strategic Focus: Abbott aims to reduce or stabilize long-term medication use, enhancing patients' quality of life.

3. Synapse Biomedical (SBI):
Overview: SBI specializes in neurostimulation products, focusing on respiratory support for patients with spinal cord injuries and ALS.

Key Product:

NeuRx® Diaphragm Pacing System (DPS): A device that stimulates the diaphragm to assist breathing in patients with chronic respiratory insufficiency.

Strategic Focus: SBI is dedicated to the research, development, and commercialization of life-altering neurostimulation products.

4. Boston Scientific Corporation:
Overview: Boston Scientific offers a range of neuromodulation therapies, including spinal cord stimulation systems, to manage chronic pain.

Key Products:

Spectra WaveWriterTM: A system designed to personalize pain relief through combination therapy and advanced programming.

Precision NoviTM: The smallest spinal cord stimulator system, providing targeted pain relief.

Precision PlusTM: Features 16 contacts and dedicated power sources for precise targeting of pain.

Strategic Focus: Boston Scientific aims to provide personalized pain relief, even when other therapies have failed.

5. Curonix LLC:
Overview: Curonix is a privately held company specializing in advanced neurostimulation solutions for chronic pain management.

Key Product:

Freedom® Spinal Cord Stimulator System: A chronic pain solution for intractable pain of the trunk and/or lower limbs, featuring a battery-free implant and wearable accessory.

Strategic Focus: Curonix is committed to developing innovative therapies to relieve chronic pain and improve patients' quality of life

FDA Approvals:

Boston Scientific - New SCS Leads
In July 2025, Boston Scientific announced FDA approval for new SCS leads compatible with its W4 and D4 lead splitters. These leads offer a broader range of percutaneous configurations, enhancing treatment options for chronic pain management.

Saluda Medical - EVA Programming Platform
Saluda Medical received FDA approval in January 2025 for its EVA platform, the first automated programming system for SCS devices. This innovation aims to streamline patient programming by autonomously analyzing nerve responses, potentially reducing clinic workload and enhancing patient outcomes.

Onward Medical - ARC-EX System
In December 2024, the FDA granted de novo classification to Onward Medical's ARC-EX system for spinal cord injury patients, marking a significant step forward in restoring hand function for individuals with severe spinal cord injuries.

Mergers & Acquisitions:

1. Boston Scientific Acquires Nalu Medical
On October 17, 2025, Boston Scientific announced its acquisition of Nalu Medical for approximately $533 million. Nalu's miniaturized, battery-free peripheral nerve stimulation device complements Boston Scientific's existing neuromodulation portfolio, aiming to expand its chronic pain treatment offerings.

2. Globus Medical Acquires Nevro
In a strategic move, Globus Medical acquired Nevro, a company specializing in SCS devices, for $250 million. This acquisition underscores the growing focus on innovative pain management solutions and aims to enhance Globus Medical's presence in the chronic pain management market.

3. Nevro Acquires VYRSA Technologies
In November 2023, Nevro acquired VYRSA Technologies for $40 million upfront, with additional milestone payments. This acquisition diversifies Nevro's product offerings and expands its market reach in chronic pain treatment.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=spinal-cord-stimulation-market

Segments Covered in the Spinal Cord Stimulation Market:

1. By Product Type
Implantable Pulse Generators (IPGs): Devices that generate electrical pulses delivered to the spinal cord.

Rechargeable IPGs: Can be recharged and last longer; higher initial cost but cost-effective over time.

Non-rechargeable IPGs: Single-use batteries, simpler but require replacement surgery.

Leads: Wires that carry electrical signals from IPG to spinal cord.

Percutaneous Leads: Minimally invasive, inserted through a needle.

Surgical Leads: Paddle-shaped, implanted via surgery; more stable placement.

Trial Systems: Temporary devices used to test patient response before permanent implantation.

2. By Application / Indication
Chronic Pain: Most common use, including:

Failed Back Surgery Syndrome (FBSS)

Complex Regional Pain Syndrome (CRPS)

Peripheral Neuropathy: Nerve pain due to diabetes or injury.

Angina / Ischemic Heart Disease: Emerging applications for cardiovascular conditions.

Other Indications: Includes pain from spinal cord injuries or multiple sclerosis.

3. By End-User
Hospitals & Clinics: Major segment due to advanced infrastructure and skilled staff.

Ambulatory Surgical Centers (ASCs): Growing preference for minimally invasive implantation.

Specialty Pain Centers: Focused treatment for chronic pain patients, often using SCS as part of multidisciplinary care.

4. By Geography
North America: Largest market due to advanced healthcare infrastructure, awareness, and reimbursement coverage.

Europe: Significant adoption with established reimbursement policies.

Asia-Pacific: Rapid growth due to rising healthcare expenditure and increasing chronic pain prevalence.

Rest of the World: Emerging opportunities in Latin America, Middle East, and Africa.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Spinal Cord Stimulation Market in 2025?
◆ What is the projected growth rate of the Spinal Cord Stimulation Market through 2033?
◆ Who are the key players in the Spinal Cord Stimulation Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.